Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

New Sheba Study Indicates That Ivermectin Can Reduce the Length of COVID-19 Infection

Ivermectin Can Reduce the Length of COVID-19 Infection
Ivermectin is being used on COVID-19 patients, and is an FDA approved broad-spectrum antiparasitic agent, most commonly used in developing countries

While the fight against the COVID-19 pandemic continues around the world, many countries still lack adequate supplies of vaccines. However, even in Israel, which has the highest vaccination rates in the world, doctors are looking ahead and attempting to find treatments that will address the possibility of future mutations and help countries that lack the necessary funds to purchase large stocks of vaccines.

According to a new study conducted at Sheba’s Center for Travel Medicine and Tropical Disease, one viable and readily available treatment option can be found in Ivermectin, a broad-spectrum antiparasitic agent, most commonly used in developing countries. The study, directed by Prof. Eli Schwartz, indicated that Ivermectin reduces the duration of COVID-19 infection.

According to Prof. Schwartz: “We decided to go for Ivermectin because we knew its safety profile well … I decided to test it on patients during the early stages of the disease, to see if it can act a bit like a vaccine and shorten or prevent the contagious stage, and thus break the transmission chain and shorten the isolation period … the study showed that Ivermectin really acted well and shortened the contagious period … The results are very encouraging, and indicate that the drug has antiviral effects.”

Sheba DUNS 100

For The Second Consecutive Year: Sheba Tops the Healthcare Sector on Dun & Bradstreet’s List of Leading Organizations

Dun & Bradstreet, the world’s foremost commercial data company, ranked 71 doctors from Sheba Medical Center in its list of the top Israeli clinical experts.…
Read More

Ayelet’s Miracle: The First Woman to Conceive Four Children Following Ovarian Tissue Cryopreservation

At 21, Ayelet Rozenberg was diagnosed with Hodgkin’s lymphoma. Facing aggressive therapies necessary to save her life, Ayelet feared she would never be able to…
Read More
bowel disease
News Sep 07.

Sheba Partners with Biomica to Advance Inflammatory Bowel Disease Care

As part of the new collaboration, Sheba and Biomica will engage in joint microbiome clinical research to develop better treatments for inflammatory bowel disease (IBD)…
Read More